KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Tax Provisions (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Tax Provisions readings, the most recent being $67.0 million for Q1 2026.

  • On a quarterly basis, Tax Provisions fell 9.46% to $67.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$187.0 million, a 123.35% decrease, with the full-year FY2025 number at -$180.0 million, down 126.63% from a year prior.
  • Tax Provisions hit $67.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from -$390.0 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $630.0 million in Q2 2024 to a low of -$900.0 million in Q2 2022.
  • Median Tax Provisions over the past 5 years was $28.0 million (2024), compared with a mean of -$5.1 million.
  • Biggest five-year swings in Tax Provisions: surged 4037.5% in 2024 and later plummeted 1492.86% in 2025.
  • Teva Pharmaceutical Industries' Tax Provisions stood at $149.0 million in 2022, then crashed by 72.48% to $41.0 million in 2023, then plummeted by 31.71% to $28.0 million in 2024, then plummeted by 1492.86% to -$390.0 million in 2025, then soared by 117.18% to $67.0 million in 2026.
  • The last three reported values for Tax Provisions were $67.0 million (Q1 2026), -$390.0 million (Q4 2025), and $214.0 million (Q3 2025) per Business Quant data.